에서 실시간으로 운영 중이에요! 자세히 알아보기

Assembly Biosciences

ASMB

시가총액 US$4.09억

20.09 USD

-0.48

2.33%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-2.33%

5일

-14.26%

1개월

-21.15%

3개월

-22.25%

6개월

-31.48%

연초 이후

-40.47%

1년

-30.91%

5년

-47.85%

10년

-85.86%

소개: Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

직원 수: 73

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 70%

중립 30%

부정적 0%

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

Zacks Investment Research

Best Momentum Stocks to Buy for September 17th

MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.

Best Momentum Stocks to Buy for September 17th

Zacks Investment Research

New Strong Buy Stocks for September 17th

MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.

New Strong Buy Stocks for September 17th

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

Zacks Investment Research

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Zacks Investment Research

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

Zacks Investment Research

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Zacks Investment Research

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.

5 Stocks With Recent Price Strength Buoyed by a Strong August

Zacks Investment Research

Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.